- HER2+ gastric cancer refers to a subtype of gastric cancer characterized by an overexpression of the HER2 (human epidermal growth factor receptor 2) protein. This protein promotes cancer cell growth, and its overexpression can lead to more aggressive tumor behavior. HER2+ gastric cancer is often diagnosed through biopsy or blood tests that detect the presence of high HER2 levels on cancer cells
- The HER2+ gastric cancer market’s growth is primarily driven by the increasing prevalence of the condition and advancements in targeted therapies. Targeted therapies, such as trastuzumab (Herceptin), have significantly improved patient outcomes by specifically targeting HER2 receptors on cancer cells, preventing tumor growth and spread. As more treatments are developed to target HER2, and as early diagnosis improves, the demand for these therapies is expected to rise
- For instance, In June 2021, FDA approved trastuzumab deruxtecan (Enhertu) for the treatment of HER2-positive gastric cancer. This approval was based on clinical trial data showing significant improvements in progression-free survival and overall response rates, offering a new targeted treatment option for patients with advanced HER2+ gastric cancer
- Moreover, an aging population and lifestyle factors contributing to gastric cancer incidence are expected to further drive market growth. Ongoing research and the development of novel HER2-targeted therapies will likely continue to shape the landscape of HER2+ gastric cancer treatment
